Trials / Completed
CompletedNCT00299494
Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)
A Phase 1/2 Study Of Cmc-544 Administered In Combination With Rituximab In Subjects With Follicular Or Diffuse Large B-cell Non-hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 119 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine the tolerability, the initial safety profile and maximum tolerated dose, and to obtain preliminary information on the antitumor activity of inotuzumab ozogamicin \[CMC-544\] in combination with rituximab in subjects with follicular, diffuse large B-Cell, or mantle cell NHL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | inotuzumab ozogamicin | IV, 1.8 mg/m2, q4w |
| DRUG | inotuzumab ozogamicin | IV, 1.8 mg/m2, q4w |
| DRUG | inotuzumab ozogamicin | IV, 1.8 mg/m2, q4w |
| DRUG | Rituximab | rituximab 375 mg/m\^2 via IV infusion on Day 1 |
Timeline
- Start date
- 2006-05-04
- Primary completion
- 2014-05-19
- Completion
- 2014-06-02
- First posted
- 2006-03-06
- Last updated
- 2018-03-08
- Results posted
- 2018-03-08
Locations
38 sites across 13 countries: United States, Australia, Belgium, France, Germany, Hong Kong, Italy, Netherlands, Poland, South Korea, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00299494. Inclusion in this directory is not an endorsement.